Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform
Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.
The Company also announced that it has raised $3 million funding, which will enable in-house development of the antibodies showing the highest affinity blocking function, making them ideal starting points as therapeutic assets.
The antibodies were identified using Antiverse’s proprietary computational antibody drug discovery platform, which uses machine learning to model antibody-antigen interactions and design de novo antibodies. The platform was used to identify a diverse set of binders to two structurally distinct GPCRs, and following Fluorescence-Activated Cell Sorting (FACS), 8 antibodies were identified as human GPCR binders. 7 of these binders were confirmed as antagonists, blocking GPCR activity.
